

IN THE CLAIMS

1. (Previously Presented) A method of treating sexual dysfunction which comprises administering to a subject suffering therefrom and in need of treatment an effective amount of a bombesin receptor antagonist.
2. (Cancelled)
3. (Cancelled)
4. (Original) The method of claim 1, wherein the dysfunction is associated with generalized unresponsiveness and ageing-related decline in sexual arousability or with drug-induced sexual dysfunction.
5. (Original) The method of claim 1, wherein the subject is a human female.
6. (Original) The method of claim 1, wherein the subject is a human male.
7. (Original) The method of claim 2, wherein the bombesin receptor antagonist has a preferential affinity for the BB₁ receptor.
8. (Original) The method of claim 1, wherein there is administered to the subject an effective amount of a non-peptide receptor antagonist.
9. (Original) The method of claim 8, wherein the non-peptide bombesin receptor antagonist is a compound that is absorbable when administered orally.
10. (Original) The method of claim 1, wherein there is administered to the subject an effective amount of a bombesin receptor antagonist which is a peptide.

11. -13. (Cancelled)

14. (Previously presented) The method of claim 1, wherein the bombesin receptor antagonist is administered in combination with alprostadil or phentolamine.

15. (Cancelled)

16. (Previously Presented) The method of Claim 1, wherein the bombesin receptor antagonist is administered in combination with L-arginine or a PDE 5 inhibitor.

17. (Original) The method of claim 1, which comprises administering to a subject a bombesin receptor antagonist in combination with a modulator of steroid hormones, a steroid hormone or a hormone product useful for the treatment of sexual dysfunction.

18. (Original) The method of claim 17, wherein the steroid hormone is selected from oestrogens or androgens.

19. (Previously Presented) The method of claim 1, which comprises administering to a subject a bombesin receptor antagonist in combination with a second agent comprising catecholamine agonist, a 5HT₂ antagonist, a monoamine synthesis modifier, or a monoamine metabolism or uptake modifier useful for the treatment of sexual dysfunction.

20. (Previously Presented) The method of claim 19, wherein the second agent is selected from quinelorane, ritaneserin, para-chlorophenylalanine or imipramine.

21. (Previously Presented) The method of claim 1, wherein the bombesin receptor antagoninist and a vasodilator are simultaneously

administered to the subject in the form of a composition containing a unit dose of the bombesin receptor antagonist, a unit dose of the vasodilator and a pharmaceutically acceptable carrier or diluent.

22. (Original) The method of claim 17 wherein the bombesin receptor antagonist and the modulator of steroid hormones, steroid hormone or hormone product are simultaneously administered to the subject in the form of a composition containing a unit dose of the bombesin receptor antagonist, a unit dose of the modulator of steroid hormones, steroid hormone or hormone product and a pharmaceutically acceptable carrier or diluent.

23. (Previously Presented) The method of claim 19 wherein the bombesin receptor antagonist and the catecholamine agonist, 5HT₂ antagonist, monoamine synthesis modifier, or monoamine metabolism or uptake modifier are simultaneously administered to the subject in the form of a composition containing a unit dose of the bombesin receptor antagonist, a unit dose of the catecholamine agonist, 5HT₂ antagonist, monoamine synthesis modifier, or monoamine metabolism or uptake modifier and a pharmaceutically acceptable carrier or diluent.

24. (Previously presented) The method of claim 5, wherein the sexual dysfunction is hypoactive sexual desire disorder.

25. (Previously presented) The method of claim 5, wherein the sexual dysfunction is a sexual arousal disorder.

26. (Previously presented) The method of claim 5, wherein the sexual dysfunction is a orgasmic disorder or anorgasmy.

27. (Previously presented) The method of claim 5, wherein the sexual dysfunction is sexual pain disorder.

28. (Previously presented) The method of claim 5, wherein the subject is receiving an antidepressant or antihypertensive.

29. (Previously presented) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a vasodilator which acts on local blood flow at the clitoris or vagina or on lubricant secretion.

30. (Previously presented) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a PDE5 inhibitor.

31. (Previously presented) The method of claim 30, wherein the PDE5 inhibitor is sildenafil or a pharmaceutically acceptable salt thereof.

32. (Cancelled)

33. (Previously Presented) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an angiotensin-2 receptor antagonist.

34. (Previously presented) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an oestrogen.

35. (Previously presented) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with androgen.

36. (Previously Presented) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a catecholamine agonist or 5HT₂ antagonist.

37. (Previously presented) The method of claim 6, wherein the sexual dysfunction is erectile dysfunction.

38. (Previously presented) The method of claim 6, wherein the sexual dysfunction is psychogenic.

39. (Previously presented) The method of claim 6, wherein the sexual dysfunction is drug-induced.

40. (Previously presented) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a vasodilator which acts on local blood flow at the penis.

41. (Previously presented) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a PDE5 inhibitor.

42. (Previously presented) The method of claim 6, wherein the PDE5 inhibitor is sildenafil or a pharmaceutically acceptable salt thereof.

43. (Cancelled)

44. (Previously Presented) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with an angiotensin-2 receptor antagonist.

45. (Previously presented) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with an androgen.

46. (Previously Presented) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a catecholamine agonist, 5HT₂ antagonist.